방사선종양학

본문글자크기
  • [Oncol Lett .] Safety of hypofractionated volumetric modulated arc therapy for early breast cancer: A preliminary report

    한양대 한마음창원병원 / 이정원, 정미주*

  • 출처
    Oncol Lett .
  • 등재일
    2023 Jun 15
  • 저널이슈번호
    26(2):330. doi: 10.3892/ol.2023.13916. eCollection 2023 Aug.
  • 내용

    바로가기  >

    Abstract
    The present study attempts to evaluate the acute and subacute toxicities of hypofractionated volumetric modulated arc therapy (HFX-VMAT) in patients with early breast cancer (EBC). It is a retrospective analysis of 23 patients treated with HFX-VMAT after breast-conserving surgery between September 2021 and February 2022. A total dose of 50.05 to 52.55 Gy was delivered, consisting of 40.05 Gy to the ipsilateral whole breast in 15 fractions of 2.67 Gy and a tumor bed boost dose of 10-12.5 Gy in 4-5 fractions. The primary endpoint was acute/subacute radiation pneumonitis (RP). The secondary endpoint was poor cosmesis, indicating acute/subacute radiation dermatitis. Chest computed tomography (CT) and the Common Terminology Criteria for Adverse Events v.5.0 were used to assess acute and subacute RP and dermatitis, respectively, during radiotherapy (RT) and at 3- and 6-months post-RT. The median follow-up duration was 3.8 months (range, 2.3-4.2). A total of seven patients developed RP. None of these patients presented RP-related symptoms; the diagnosis was based on radiologic findings observed on follow-up chest CT. Among the seven patients with RP, five had right-sided, and two had left-sided breast tumors (71.4 vs. 28.6%; P=0.026). Grade 1 erythema was observed in 19 patients (82.6%) and grade 2 erythema in four (17.4%). The mean target dose, D105% (the dose received by 105% of the target volume), homogeneity index, mean lung dose, ipsilateral lung V20 (the percentage volume receiving 20 Gy), and V30 (the percentage volume receiving 30 Gy) for ipsilateral whole breast RT were significantly associated with RP (P=0.039, 0.047, 0.018, 0.015, 0.018 and 0.003, respectively.). HFX-VMAT showed tolerable acute/subacute toxicities. Therefore, HFX-VMAT is an effective and safe treatment option for EBC.

     

     

    Affiliations

    Jeong Won Lee 1, Mi Joo Chung 2
    1Department of Radiation Oncology, Daegu Catholic University School of Medicine, Daegu, North Gyeongsang 42472, Republic of Korea.
    2Department of Radiation Oncology, Hanyang University Hanmaeum Changwon Hospital, Changwon, Gyeongsangnam 51139, Republic of Korea.

  • 키워드
    acute toxicity; breast cancer; hypofractionated radiotherapy; radiation dermatitis; radiation pneumonitis; volumetric modulated arc therapy.
  • 덧글달기
    덧글달기
       IP : 3.15.147.53

    등록